Loading
companiesCompany
Intas Pharmaceuticals (Accord Healthcare)
A privately held Ahmedabad company whose European arm, Accord Healthcare, is one of the largest suppliers of generic chemotherapy and supportive-care biosimilars to European hospitals.
Overview
Intas was founded in 1977 by Hasmukh Chudgar and incorporated in 1985; it operates 22 manufacturing plants and sells in more than 100 countries, with revenue heading toward 24,000 crore rupees. Its Biologics Unit was the first Indian company to receive EU GMP certification (April 2007), and its London-based subsidiary Accord Healthcare markets generics and biosimilars across Europe and North America, including the pegfilgrastim biosimilar Pelgraz (EMA authorisation 21 September 2018) used to prevent chemotherapy-induced neutropenia. Accord's injectable oncology generics are a staple of European hospital pharmacies.
Similar pages
- CompanyDr. Reddy's Laboratories
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Biosimilar, Generic sterile injectables (the 2023 platinum shortage).
- CompanyViatris
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Biosimilar, Generic sterile injectables (the 2023 platinum shortage).
- CompanySandoz
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Generic sterile injectables (the 2023 platinum shortage).
- CompanyAmneal Pharmaceuticals
Shares Oral solid dose manufacturing (tablets and capsules), Generic sterile injectables (the 2023 platinum shortage).
- CompanyCipla
Shares Oral solid dose manufacturing (tablets and capsules), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Cytotoxic chemotherapy.
- CompanyBiocon
Shares Biosimilar manufacturing and comparability, Biosimilar, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Cytotoxic chemotherapy.
- TechnologySmall-molecule API synthesis
Shares GMP, inspections, Form 483s and warning letters, Oral solid dose manufacturing (tablets and capsules), Generic sterile injectables (the 2023 platinum shortage), Prices and value.